Hidradenitis suppurativa (acne inversa)
hidradenitis suppurativa, acne inversa, HS, Hurley stage, axillary abscess, adalimumab, bimekizumab · Dermatology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic relapsing inflammatory disease of the apocrine-gland-bearing flexures (axillae, groin, perineum, inframammary, buttocks) with recurrent painful nodules, abscesses, draining sinus tracts and scarring. Driven by follicular occlusion and inflammation; associated with smoking, obesity, metabolic syndrome, and inflammatory bowel disease. Hugely painful and under-treated; often misdiagnosed as recurrent boils.
Red flags
- Severe sepsis from superinfected lesions
- Rapid change / non-healing ulceration within long-standing tracts - rare squamous cell carcinoma (esp. perineal/buttock, long-standing disease)
- New bowel symptoms / perianal disease suggesting Crohn's
- Severe uncontrolled pain and disability; depression/suicidality
- Anaemia of chronic disease / amyloidosis in severe disease
Assessment
Differential diagnosis
- Recurrent furunculosis / carbuncle
- Crohn's disease (metastatic / perianal)
- Epidermoid / pilonidal cysts
- Lymphogranuloma venereum / STI bubo
- Cutaneous tuberculosis / actinomycosis
- Anal fistula
- Acne conglobata (follicular occlusion tetrad)
Investigations
- Clinical diagnosis: typical lesions, typical flexural sites, recurrence/chronicity; stage by Hurley (I-III) and severity by IHS4
- Swab draining pus if superinfected (but lesions are often sterile/mixed flora) [verify local]
- Screen comorbidities: BMI, smoking status, HbA1c/glucose, lipids, and ask about IBD/arthropathy; depression screen
- Inflammatory markers (CRP) if severe/systemic
- Ultrasound or MRI to map sinus tracts before surgery (specialist)
Management
- Confirm diagnosis and stage (Hurley I-III); explain chronic nature and treatment ladder
- General: smoking cessation, weight optimisation, loose clothing, antiseptic washes, analgesia, treat flares promptly; manage pain and mental health
- Mild (Hurley I / localised): topical clindamycin; intralesional corticosteroid for acute flare nodules
- Moderate: oral tetracycline course, or oral clindamycin + rifampicin combination for 10-12 weeks
- Acute abscess/flare: incision and drainage or de-roofing for pain relief (but simple I&D often recurs - prefer de-roofing)
- Moderate-severe / refractory: biologic therapy - adalimumab, secukinumab or bimekizumab (EMA/approved); refer to dermatology
- Chronic sinus tracts/scarring (Hurley III): wide surgical excision of affected area - definitive for localised burnt-out tracts
- Multidisciplinary care: dermatology, surgery, pain, dietetics, psychology
Drugs & doses
Topical clindamycin 1% solution twice daily (Hurley I / mild)
Intralesional triamcinolone 5-10 mg/mL injected into acute inflammatory nodule [verify local dose]
Doxycycline or lymecycline 100 mg / 408 mg ORAL once daily for 12 weeks [verify local]
Clindamycin 300 mg ORAL twice daily + rifampicin 300 mg ORAL twice daily for 10-12 weeks (classic combination) [verify local dose]
Adalimumab 160 mg SC week 0, 80 mg week 2, then 40 mg WEEKLY from week 4 (licensed for moderate-severe HS) [verify local]
Secukinumab 300 mg SC weekly for 5 weeks then every 2-4 weeks [verify local]
Bimekizumab per product schedule (newer EMA-approved IL-17A/F biologic) [verify local]
Antiandrogen (e.g. spironolactone, or combined OCP) in selected females [verify local]
Analgesia and short systemic steroid for severe flare per specialist [verify local]
Disposition
Outpatient dermatology-led chronic management with MDT (surgery, pain, dietetics, psychology). ED/acute: drain painful abscesses, analgesia, treat superinfection, and refer. Admit for systemic sepsis or severe uncontrolled disease.
Complications & pitfalls
- Disfiguring scarring, contractures and lymphoedema
- Chronic pain and major quality-of-life/psychological impact
- Secondary infection and sepsis
- Squamous cell carcinoma in chronic tracts
- Fistulae (to urethra/rectum), anaemia, secondary amyloidosis
- Associated metabolic syndrome and cardiovascular risk
Exam pearls
- 2024 European S2k and 2026 AAD/HS Foundation guidelines place biologics (adalimumab, secukinumab, bimekizumab, infliximab) at the centre of moderate-to-severe care; clindamycin+rifampicin and tetracyclines are systemic antibiotic options
- Often mistaken for recurrent boils - the flexural distribution, sinus tracts and chronicity are the clue; diagnose early to prevent scarring
- Simple incision and drainage recurs - de-roofing or wide excision gives durable control for localised disease
- Smoking cessation and weight loss materially improve disease
- Screen for and treat depression, IBD and metabolic syndrome
- Consider SCC in any non-healing lesion within long-standing perineal/buttock tracts
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.